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Abstract
This report revisits the accidental discovery that protection against simian immunodeficiency virus (SIV)
infection in the early successful experimental AIDS vaccine studies in Rhesus macaques was due to
antibodies directed against human leukocyte antigens (HLAs). The inactivated virus vaccine approach
was discarded because protection was due to the host’s immune reaction against the HLA acquired by
SIV from the human cell lines in which it was grown, rather than against antigenic determinants of SIV
itself. Subsequent studies have revealed that immune recognition of HLA on uninfected leukocytes also
induces other factors that inhibit infection by both SIV and the human immunodeficiency virus. Pro and
con aspects of immunization against HLA as a potential AIDS vaccine strategy are discussed.
When a negative control turns out to be positive
It was 1991—less than ten years after the cause of AIDS had
been identified—and researchers already thought
they might have a successful vaccine. Evidence from seve-
ral laboratories suggested that it was possible to develop
a vaccine against HIV by inoculating individuals with
a crippled version of the virus that could not replicate, a
strategy similar to that used to produce measles, mumps,
and polio vaccines. In their tests, researchers used a virus
similar to HIV, called simian immunodeficiency virus
(SIV), which infects Rhesus macaque monkeys. Over time
the monkeys would develop AIDS-like symptoms, much
like humans. Researchers inactivated SIV, injected it into
the monkeys as a vaccine, and tested whether the animals
were protected against live SIV infection. Indeed, several
monkeys were protected, and AIDS researchers were
encouraged that an effective human AIDS vaccine would
soon follow.
However, in October 1991, a brief article was published
that sent AIDS vaccine research into a tailspin [1]. Like
others [2,3], E. James Stott’s laboratory had immunized
macaques with inactivated SIV, which protected them
against subsequent infection with live virus. In contrast
to earlier reports, the Stott laboratory included a negative
control that was missing from the earlier studies. Thus,
a second group of monkeys was immunized with the
human host cells that had been used to grow the
inactivated SIV, but which had not been infected with
SIV and, therefore, contained no trace of the virus [1]. The
purpose of this negative control was to ensure that the
immune reaction, which had successfully protected
the monkeys, was specific for SIV antigens, and was not
induced by something other than SIV. Surprisingly, the
“negative control” produced protective immunity against
SIV infection. Equally surprising was the fact that
protection in the vaccine group was not associated with
antibodies that recognized SIV antigens.
Stott’s discovery prompted additional experiments to
elucidate the underlying mechanisms of protection. First,
HLA class I and II molecules were shown to be expressed
on the surface of HIV and SIV—enveloped viruses such
as HIV and SIV are coated with a lipid membrane that
is stolen from the host cell as the virus exits, and this
coat includes host membrane proteins including HLA.
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Interestingly, the amounts of HLA on the viruses’
envelope exceeded those of the main viral antigen
gp120 [4]. Second, immunization of macaques with
purified HLA class II protected the animals from
infection with SIV that bore the same HLA [2] but not
against SIV grown in cells that expressed different HLA.
Although some inactivated virus vaccine studies
also reported SIV-specific antibody responses [1], the
protection achieved in these studies was not due to a
classic vaccine effect, intended to generate immunologic
memory against specific viral antigens. Rather, a non-
SIV-specific experimental “artifact”, namely the immune
reaction against xenogeneic HLA, was shown to be the
cause of the protection.
Despite the fact that more than 200 macaques in several
independent studies were protected from infection [3],
presumably by anti-HLA antibodies, the whole inacti-
vated virus AIDS vaccine approach was largely discarded
in favor of pursuing vaccines that would generate HIV/
SIV-specific adaptive humoral and cellular immunity.
This was a sensible and rational decision at the time,
taken by following the rigorous scientific process of
rejecting the initial hypothesis based on the experimen-
tal results and controls. If now, almost 30 years after HIV
was isolated, an effective virus-specific vaccine against
HIV were available, there would be no reason to look
back at those experiments and revisit their outcome.
However, the limited success of some promising-looking
HIV vaccine trials in recent years prompted us to reflect
and reconsider retrospectively some of the earlier studies
on HIV/SIV vaccines. Can we learn anything from the
failed negative control of the Stott laboratory’s experi-
ment? Would we still consider the outcome of that study
to be an artifact, if instead of searching for anti-SIV
responses, we could reformulate the hypothesis and
postulate that anti-HLA reactions can protect against SIV/
HIV infections? As early on as 1993, a letter in Science
suggested that the protection induced by foreign HLA
activation should be pursued as a possible AIDS vaccine
strategy [5].
Other HLA-activated anti-SIV/HIV mechanisms
Might immunologic factors other than anti-HLA antibo-
dies have been activated by foreign HLA recognition? Such
mechanisms may have been overlooked or not detec-
ted in the earlier SIV/macaque studies, but could have
contributed to the observed protection against infection.
More recent independent studies discovered multiple
protective roles for xenoantigen- and alloantigen-activated
immunity. These components included anti-CCR5 (C-C
chemokine receptor type 5) antibodies [6], and several
innate antiviral factors in both the SIV/macaque and
HIV/human experiments. These factors include the CD8
T cell-derived anti-HIV factor (CD8-SF) [7] and the
b-chemokines RANTES (Regulated upon Activation, Nor-
mal T-cell Expressed, and Secreted), MIP-1a (macrophage
inflammatory protein-1a), and MIP-1b [8], which block
the CCR5 coreceptor, essential for virus entry into target
leukocytes. These results raise the possibility that anti-SIV
factors and anti-CCR5 antibodies also contributed to
protection against infection in the early vaccine studies.
Intentional in vivo alloimmunization of recurrent sponta-
neously-aborting women against their partners’ peripheral
blood leukocytes induced: (a) increased levels of RANTES,
MIP-1a, MIP-1b, and CD8-SF; (b) decreased CCR5 and
CXCR4 (C-X-C chemokine receptor type 4) coreceptor
expression; and (c) increased resistance to in vitro HIV
infection [8], a picture that resembled the results obtained
by xenogeneic immunization in the SIV/macaque model.
HLA alloantigen stimulation of human peripheral blood
leukocytes also induced the soluble factor EDN (eosino-
phil-derived neurotoxin) in monocytes [9] and the
cytodine deaminase APOBEC3G (A3G) in CD4+ T cells
[10]. Both EDN and A3G interfere with HIV replication in
the crucial window of opportunity after virus entry and
before reverse transcription. This effect can also been
seen in vivo, in alloimmunization of recurrent sponta-
neously-aborting women, for example, which resulted
in increased A3G that was associated with reduced CD4+
T-cell susceptibility to HIV infection in vitro [10].
A study of vertical perinatal (i.e., from mother to baby
during delivery) transmission of HIV in Kenya indicated
that babies with HLA class I similar to that of their
mother were more likely to contract HIV [11]. Similar
results were obtained in a mother/neonate study in the
United States. Several cohorts of individuals have been
identified that are repeatedly exposed to HIV, but appear
not to have become infected [12]. One cohort of HIV-
exposed seronegative patients was identified in couples
in which only one partner is HIV-infected, and who do
not use safe sexual practices. These HIV-exposed serone-
gative individuals produced anti-CCR5 serum antibodies
[13], and their peripheral blood leukocytes exhibited
elevated levels of A3G [14]. Thus, HLA alloantigen
recognition might contribute to protecting against both
vertical and horizontal HIV transmission.
None of these antiviral mechanisms may be, on its own,
sufficient to provide effective protection from SIV/HIV
infection. For example, immunization ofmacaques against
CCR5 provided partial protection from SIV challenge,
but did not achieve the same levels of protection that
had been observed in studies using inactivated SIV
vaccine [15]. However, when several mechanisms such as
the ones described above are activated simultaneously,
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they may synergize in conferring a protective effect.
Should a vaccine strategy that generates the above arsenal
of multiple innate and antibody-mediated protective
mechanisms against SIV/HIV be seriously considered as
an AIDS vaccine? This question can be now raised retro-
spectively, since the induction of the anti-HIV/SIV factors
by xenoantigen or alloantigen recognition was reported
only after the inactivated virus vaccine strategy had been
dropped.
The virus-specific AIDS vaccine approach
In March 2008, the Division of AIDS (DAIDS), National
Institute of Allergy and Infectious Diseases (NIAID) held
a summit meeting in Bethesda, Maryland, to discuss the
repeated failures that spanned a 20-year period of attempts
to develop an effective HIV antigen-specific prophylac-
tic AIDS vaccine, and to consider plans for the future. Our
subsequent commentary on the summit suggested that
innovative nontraditional approaches not bound to the
paradigm of prime-boost stimulation of adaptive immu-
nity should be considered in order to overcome some of
the characteristic features that allow HIV to escape
immune control [16].
Among the problems that undermine the effectiveness
of virus-specific AIDS vaccines is the fact that HIV bypas-
ses virus-specific immunity by mutating away from the
immunogenic viral epitopes for which a vaccine was
designed. Another important hurdle for adaptive immu-
nity is the rapid rate at which HIV and SIV infect mucosal
sites. Thus, by infecting macaques intravaginally with SIV,
Ashley Haase’s laboratory estimated that endocervical
infection occurs within a few hours of viral challenge,
resulting in rapid migration of infection-susceptible
CD4+ T cells to the site of viral exposure [17]. These
findings suggest that adaptive immune responses
induced by AIDS vaccines may be “too late, too little.”
Therefore, upon exposure to infectiousHIV/SIV, protective
mechanisms should already be active at the site of viral
challenge during this brief window of opportunity.
Advantages and disadvantages of
alloantigen-based AIDS vaccines
The potential protective effect of an alloantigen-based
AIDS vaccine must be considered alongside the disadvan-
tages that this approach may have. Predicted advantages
and disadvantages of alloantigen-based AIDS vaccines
(inactivated allogeneic HIV and/or uninfected allogeneic
leukocytes) are listed in Table 1, and are summarized in
the text below.
HLA is one of the most immunogenic molecules known.
Recognition of allogeneic leukocytes uniquely leads to
rapid primary HLA-specific responses, and immuniza-
tion with either allogeneic leukocytes or inactivated SIV
induces potent anti-HLA antibody responses. Thus,
based on the high density and immunogenic potential
of HLA on the HIV envelope [4], anti-HLA antibodies
are likely to react against HIV more efficiently than
antibodies against viral envelope antigens. Notably,
immunization with purified HLA was sufficient to
achieve protection from infection [2], demonstrating
the potency of anti-HLA antibodies in neutralizing SIV.
However, when inactivated HLA-bearing SIV was used
as a vaccine by Stott and others, they observed not only
anti-HLA protective antibodies, but also anti-SIV anti-
bodies that were induced by SIV antigens expressed
by the immunizing HIV particles [1,3]. Therefore, the
inactivated HIV/SIV approach may meet the requirement
for both antiviral and anti-HLA immunity. Noteworthy
here is the fact that those experiments of HLA-associated
immunity protected macaques from intravenous infec-
tion with high doses of virus [1,3]. Whether anti-HLA,
anti-CCR5, and other innate antiviral factors may be
Table 1. Advantages and disadvantages of alloantigen-based AIDS vaccines
Advantages Disadvantages
Induces potent anti-HLA antibody memory immunity Could exclude vaccine recipients from receiving tissue transplants
Inactivated xenogeneic SIV induces anti-SIV antibodies as well as other
mechanisms
Might induce autoimmune or other detrimental immune conditions
Inactivated xenogeneic SIV and xenogeneic cells already shown to protect
against SIV infection (>200 animals)
Could induce high frequency of HLA-specific CD4+ virus target cells
Alloimmunization of recurrent spontaneously-aborting women (>2,500)
did not show significant adverse side effects, but did show reduced in
vitro HIV infection
Innate anti-HIV factors might not exhibit immunological memory
Immunologically indifferent to viral mutation HLA types of potential HIV-infecting contacts are unknown
Induces several different innate antiviral factors, including CD8-SF, RANTES,
MIP-1a, MIP-1b, EDN, and APOBEC3G
Need to be sterilizing: if infection occurs, donor HLA is rapidly replaced
by host HLA
Induces CCR5 antibodies and reduces HIV coreceptor expression Immunity is not virus specific
CCR5, C-C chemokine receptor type 5; CD8-SF, cluster of differentiation 8-supressor factor; EDN, eosinophil-derived neurotoxin; HLA, human leukocyte
antigen; MIP-1a, macrophage inflammatory protein-1a; RANTES, Regulated upon Activation, Normal T-cell Expressed, and Secreted; SIV, simian
immunodeficiency virus.
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present at mucosal level in amounts sufficient to protect
from infection via sexual exposure is still unknown. It is
possible that the efficacy of HLA immunization might
even be higher against natural exposure to moderate (or
suboptimal) doses of virus.
An attractive feature of alloantigen-based AIDS vaccines is
that, because it would not rely on HIV epitopes,
alloimmunization would be indifferent to viral mutation.
Furthermore, the innate antiviral factors and anti-CCR5
antibodies induced by immunization with allogeneic
leukocytes inhibit SIV and HIV replication at different
points in the viral cycle. This may increase the pressure on
HIV, which is less likely to develop mutations that would
escape the multiple inhibitory mechanisms activated
by alloantigen immunization [6-10]. Most importantly, if
anti-HLA and anti-CCR5 antibodies generated by alloanti-
gen-based AIDS vaccines can be induced at mucosal sites
at the time of infectious challenge, they may exert protec-
tive activity during this narrow window of opportunity,
bypassing the “too late or too little” problem [17].
Among the arguments against using alloantigen-based
AIDS vaccines are the facts that allogeneic immunization
might induce autoimmune or other detrimental immu-
nologic conditions and exclude vaccine recipients from
future allogeneic tissue transplantation. However, the
probability that vaccine recipients would receive allografts
in the future would be low in many HIV endemic regions
of the world, and antirejection drugs could be used to
prevent allograft rejection. Furthermore, allogeneic leuko-
cytes are often transferred during blood transfusions,
and more than 2,500 recurrent spontaneously-aborting
women have received multiple immunizations (some
more than 25 years ago) from their husbands without
detected detrimental effects [18]. One counterargument to
this observation is that recurrent spontaneously-aborting
women were immunized only against their partners’HLA,
whereas immunization against multiple HLA would be
needed to induce protection from HIV infection. Never-
theless, detrimental effects associated with exposure to
different HLA types are not commonly observed in
individuals who have received multiple transfusions.
The fact that the HLA types on the surface of HIV with
which an individual will make contact would be those of
the infecting host, and therefore cannot be predicted,
presents a problem for alloantigen-based AIDS vaccines.
One possible solution would be to engineer a group of
maximally-discordant HLA haplotypes into a selected
target leukocyte cell line. This cell line could then be used
as the vaccine itself, or as the source of HIV/SIV particles to
be utilized as the vaccine. Ideally, such vaccines could
generate anti-HLA antibodies to protect against HIV/SIV
expressing several different HLA. Another pitfall of the
alloantigen-based AIDS vaccine approach may be that the
efficacy of protection could correlate inversely with the
level of HLA matching between the vaccinated individual
and the infecting virus. Thus, one would expect that, if
the vaccinated individual and infecting HIV were perfec-
tly HLA matched, there would be no protective effect
provided by anti-HLA antibodies. In this rare situation,
anti-HIV activity might be limited to the effect of
alloantigen-based AIDS vaccine-induced anti-CCR5 cor-
eceptor antibodies. Thus, the lack of HLA alloantigen
recognition would not activate antiviral factors, and
vaccine-induced anti-HLA antibodies would not recognize
the matched HLA on the infecting virus as allogeneic. On
the contrary, anti-HLA antibody-mediated protection and
innate antiviral factors would be highest with maximal
HLA discordance between the vaccinated individual and
the infecting virus. Different degrees of protection might
be observed between these two extremes, depending on
the level of HLA matching.
Another potential problem with alloantigen-based AIDS
vaccines is the relatively high frequency of HLA-specific
CD4+ T cells, which could be activated by immunization
against HLA alloantigens and may result in an increased
number of potential targets for HIV infection. The
problem of increased CD4+ T cell targets for infection,
however, would also be shared by other vaccine strategies,
including vector-based HIV-specific vaccines [19].
Whether an increase in the number of targets for
infection could be counteracted by the multiple protective
mechanisms that an alloantigen-based AIDS vaccine
would induce is unknown. The only clue comes from
early macaque studies involving xenoimmunization
showing that anti-HLA antibody [1-3], and probably
innate antiviral factors and anti-CCR5 antibodies,
appeared to overcome any increase in HLA-specific
CD4+ T-cell targets, ultimately protecting the host from
infection.
One major concern for the immune responses induced by
alloantigen-based AIDS vaccines is whether they would
induce long-lasting protection and immunologic memory.
Anti-HLA antibody responses are known to be maintained
for several years. HLA alloimmunization of recurrent
spontaneously-aborting women indicated that reduced
CCR5 coreceptor expression was maintained for at least
12 months, the period of follow-up after alloimmuniztion
[8]. However, innate responses may be different, because
the same study indicated that the b-chemokines were
detected for only 6 months after alloimmunization [8].
Thus, the innate mechanisms that participate in the
protective response may bemore short-lived than adaptive
immune responses. This could be advantageous because
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long-term innate responses, if achieved, might be detri-
mental to the host. A3G was reported in memory T cells,
suggesting that this antiretroviral factor might not be so
time-critical [10]. Although these innate factors might not
be sufficient by themselves to protect against infection,
they could contribute to protection against mucosal
infection if activated in the presence of vaccine-induced
pre-existing anti-HLA and anti-CCR5 antibodies. Further-
more, it is possible that once immunized against allo-
geneic HLA, subsequent natural exposures to HIV bearing
allogeneic HLA molecules would repeatedly boost anti-
HLA and anti-CCR5 antibody responses, as well as rapidly
reactivate the transient antiviral factors.
Another problem to be overcome is that the HLA carried
by the viral envelope would remain allogeneic only as
long as infection did not occur (Figure 1). If the arsenal
of antiviral mechanisms induced by HLA recognition
failed to prevent infection of the host target cells, newly
produced HIV particles would carry the HLA of the host,
which would not be recognized as foreign. Thus, the
window of opportunity for an alloantigen-based AIDS
vaccine to be protective would be strictly time-limited,
and vaccine-induced antibodies and innate antiviral
factors (the second line of defense) would optimally
need to prevent infection, since they may not efficiently
suppress viral replication once HIV has acquired self HLA
from the host (Figure 1b). Therefore, by definition, an
effective alloantigen-based AIDS vaccine would have
to be sterilizing and could not permit infection to be
established (Figure 1a). Again, the only clue we have as
to whether this would work is the fact that more than
200 xenoantigen-immunized macaques were protected
against SIV infection [3].
Comparing different approaches for an
alloantigen-based AIDS vaccine
We have summarized the mechanisms by which HLA
recognition may result in protection from HIV/SIV.
However, it should be noted that not all of these poten-
tially protective mechanisms were: (a) tested using both
inactivated HIV/SIV and allogeneic or xenogeneic
uninfected cells; (b) studied in both the SIV/macaque
(xenogeneic) and HIV/human (allogeneic) models; and
(c) analyzed using both in vitro and in vivo systems. These
issues should be carefully investigated in comprehensive
and purpose-designed in vitro and in vivo studies to
properly appreciate the potential for an alloantigen-based
AIDS vaccine approach. For example, it is not known
whether inactivated virus would induce anti-CCR5 anti-
body and/or activate some or all of the innate antiviral
factors induced by alloimmunization of humans in vivo.
However, there are clues that it might work. Firstly,
xenogeneic leukocyte immunization of macaques was
reported to induce anti-HLA antibodies [1-3] andmucosal
immunization of macaques with macaque allogeneic
peripheral blood leukocytes (instead of xenogeneic
human cell lines) activated SIV-inhibiting chemokines,
increased anti-CCR5 antibody levels and was associated
with decreased in vitro SIV infectivity [20]. Secondly, some
of these features were seen in recurrent spontaneously-
aborting women who produced elevated levels of
b-chemokines and A3G upon alloimmunization, and
their CD4+ T cells were protected against in vitro infection
by HIV [8,10].
Would immunization using inactivated virus or purified
HLA be more effective? To complete a meaningful
comparative analysis of these two alloantigen-based
AIDS vaccine strategies, additional in vivo macaque
immunization and live mucosal SIV challenge studies
may need to be performed. These studies should compare
animals immunized with inactivated virus, animals
immunized with purified HLA, and negative control
animals for antibodies against HLA and CCR5, and for
innate antiviral factors. The kinetics with which these
factors are re-activated in the first hours after SIV challenge
at both the mucosal and systemic levels should be
monitored because of the “too late, too little” issue.
The argument can be made that xenoantigen-expressing
cells may be more potent immunogens than alloantigen-
expressing cells, which could have provided the protec-
tion observed in the Stott’s experiment [1]. However,
macaques immunized with allogeneic peripheral blood
leukocytes were protected against infection by SIV
grown in simian cells [2]. Additionally, a subsequent
study indicated that mucosal immunization with
allogeneic peripheral blood leukocytes resulted in
induction of CD8-SF, MIP-1a, MIP-1b and anti-CCR5
antibody, and increased resistance to SIV infection [20].
In humans, administration of inactivated HIV-1
(Remune) as an immunotherapeutic vaccine resulted in
the induction of antibody responses against HLA class I
and II present in the human cell line used for virus
production [21]. These findings indicate that immuniza-
tion with allogeneic cells may induce protective effects
similar to those obtained using xenogeneic cell lines.
Nevertheless, future experiments should include testing
macaque allogeneic leukocytes as a vaccine.
Although alloimmunization might induce some anti-HIV
antibodies, due to the partial three-dimensional homol-
ogy betweenHLA andHIV gp120 [5], the use of allogeneic
cells instead of inactivated virus has the disadvantage
of not including the generation of HIV-specific adaptive
T cell immunity. Thus, an inactivated HIV vaccine strategy
that also incorporates alloimmunization may combine
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Figure 1. A successful alloantigen-based AIDS vaccine (ABAV) would need to induce sterilizing immunity
(a) Upon exposure to HIV particles carrying allogeneic human leukocyte antigen (HLA), preformed anti-HLA antibodies in the immunized host will opsonize
and block challenging HIV. Anti-CCR5 (C-C chemokine receptor type 5) antibodies and b-chemokines will inhibit HIV interaction with its coreceptor and,
in case HIV successfully enters target cells, intracellular restriction factors such as eosinophil-derived neurotoxin (EDN) and APOBEC3G will prevent
productive infection. This allogeneic HLA-induced arsenal of antibodies and antiviral factors may efficiently prevent infection (“sterilizing” immunity) and result
in full protection. (b) If alloantigen-based AIDS vaccine-induced antiviral mechanisms fail to prevent productive infection, newly produced HIV particles
budding from the host’s cells will carry self HLA and will not be recognized as allogeneic anymore. Anti-HLA antibodies will not react with self HLA-carrying
HIV, antiviral factors would not be produced to counteract the spread of the infection, and anti-CCR5 antibody induced by alloantigen-based AIDS vaccines
might not offer sufficient protection.
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the above described benefits of an alloantigen-based
AIDS vaccine with the potential for generating memory
HIV-specific responses. An argument could be made that
the use of allogeneic cells would avoid the risk of exposing
vaccinees to incompletely inactivated HIV.
We are aware of only one international workshop on
alloimmunization as an alternative AIDS vaccine strat-
egy. That workshop was held in 1999 [18], before
anticoreceptor antibodies and most of the above-noted
innate anti-SIV/HIV factors were reported to result from
HLA alloimmunization. The more recent and increasing
body of evidence showing different alloinduced mechan-
isms of interference with HIV replication and infection
suggest that it may be time to reassess this alternative
vaccine strategy.
Summary
This report reconsiders an AIDS vaccine approach that
was discarded 20 years ago because it was not virus-
specific. The unorthodox and seemingly counter-scientific
approach, conceptually based on a “failed” negative
control, takes advantage of the facts that: (a) immunolo-
gically-potent HLA acquired from infected cells are carried
on the HIV envelope; and (b) these transplantation
antigens are allogeneic to the susceptible host at the time
of exposure to infectious HIV. We view expression of
foreign HLA as a transient Achilles heel for HIV, which
creates a brief window of opportunity in which pre-
formed, on-site anti-HLA and anti-CCR5 antibodies could
initially block or limit virus entry. The additional
alloantigen-based AIDS vaccine-induced arsenal of anti-
viral factors could provide a one-two punch to prevent
productive infection.
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